medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2011, Number 1

<< Back Next >>

Rev Invest Clin 2011; 63 (1)

Genetic abnormalities in leukemia secondary to treatment in patients with Hodgkin’s disease

Salas C, Pérez-Vera P, Frías S

Language: English
References: 42
Page: 53-63
PDF size: 155.08 Kb.


ABSTRACT

Hodgkin’s disease has been treated mainly with two chemotherapy schedules, MOPP (nitrogen mustard, Oncovin, procarbazine and prednisone), which includes alkylating agents, and ABVD (adriamycin, bleomycin, vinblastine and dacarbazine), which includes topoisomerase II inhibitors, either with or without radiation therapy. Due to the types of agents used, patients with Hodgkin’s disease often develop secondary leukemias. The alkylating agents included in the MOPP scheme were the first drugs associated with the development of therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML); both entities are the result of the clonal selection of cells with accumulated genomic lesions induced by antineoplastic therapy. In patients who developed t-MDS and t-AML, eight alternative routes with specific cytogenetic and molecular changes have been identified, and the routes are related to the type of therapy, alkylating agents or DNA topoisomerase II inhibitors. At the cytogenetic level, patients treated with alkylating agents show deletion 5q/ monosomy 5 and deletion 7q/monosomy 7; in contrast, those who were treated with topoisomerase II inhibitors show 11q23 translocations involving the MLL gene. At the molecular level, there are two types of mutations: Class I, which alter the RAS-BRAF signal transduction pathways and increase cell proliferation; Class II, which disrupt genes that encode transcription factors and NPM1 that are involved in cell differentiation, and the inactivation of p53 tumor suppressor gene. Knowledge of the genetic alterations in these conditions is important for the classification, treatment and prognosis of patients as well as essential for increasing the knowledge of the biology of these diseases, which leads to identifying potential therapeutic targets.


REFERENCES

  1. Fairley TL, Hawk H, Pierre S. Health behaviors and quality of life of cancer survivors in Massachusetts, 2006: data use for comprehensive cancer control. Prev Chronic Dis 2010; 7(1). http://www.cdc.gov/pcd/issues/2010/jan/09_ 0062.htm. Accessed 9th July 2010.

  2. Arden-Close E, Pacey A, Eiser C. Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma 2010; 51(4):628-40.

  3. Frías S. Consecuencias genéticas del tratamiento antineoplásico en células germinales de pacientes con cáncer. In: Rivera Luna R. Oncología pediátrica: conceptos básicos y clínicos. México: Intersistemas S.A. de C.V.; 2002, p. 279-302.

  4. Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Glimelius B, et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 2008; 45: 142-6.

  5. Leone G, Fianchi L, Pagano L, Voso MT. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact 2010; 184: 39-45.

  6. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-51.

  7. Povrik LF, Shuker DE. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 1994; 318: 205-26.

  8. Delwail V, Jais J-P, Colonna P, Andrieu J-M. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin´s disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. BJ Haematol 2002; 118: 189-94.

  9. Hudson MM, Donaldson SS. Treatment of pediatric Hodgkin´s lymphoma. Semin Hematol 1999; 36(3): 313-23.

  10. Frías S, Van Hummelen P, Marvin L, Meistrich ML, Lowe XR, Hagemeister FB, Shelby MD, et al. NOVP chemotherapy for Hodgkin´s disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18 and 21. Cancer Res 2003; 63: 44-51.

  11. Thomson AB, Wallace WHB. Treatment of paediatric Hodgkin´s disease: a balance of risks. Eur J Cancer 2002; 38: 468-77.

  12. Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology 2007; 453-9.

  13. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodiaplasia and therapy-related acute myeloid leukemia. Blood 1995; 86(9): 3542-52.

  14. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006; 20: 1943-9.

  15. Brusa G, Zuffa E, Hattinger CM, Serra M, Remondini D, Castellani G, Righi S, et al. Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. Oncol Reports 2007; 18: 1427-34.

  16. Voso MT, D’Aló F, Greco M, Fabiani E, Criscuolo M, Migliara G, Pagano L, et al. Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact 2010; 184: 46-9.

  17. Fabiani E, D’Aló F, Scardocci A, Greco M, Di Ruscio A, Criscuolo M, Fianchi L, et al. Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic síndromes. Leukemia Res 2009; 33: 1068-71.

  18. Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004; 10: 2675-80.

  19. Jawad M, Seedhouse CH, Russell N, Lumb N. Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia. Blood 2006; 108(12): 3916-8.

  20. Pedersen-Bjergaard J, Christiansen DH, Andersen MK, Skovby F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia 2002; 16: 2177-84.

  21. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Thera py-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95(11): 3273-9.

  22. Pedersen-Bjergaard J, Specht L, Larsen SO, Ersboll J, Struck J, Hansen MM, Hansen HH, et al. Risk of therapy-related leukemia and preleukemia after Hodgkin’s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987; 2(8550): 83-8.

  23. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008; 35(4): 418-29.

  24. Kaina B. Mechanisms and consequences of methylating agent-induced SCEs and chromosomal aberrations: a long road traveled and still a far way to go. Cytogenet Genome Res 2004: 77-86.

  25. Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, Björk J, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002; 16: 2366-78.

  26. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008; 22: 240-8.

  27. Pedersen-Bjergaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology 2007; 392-7.

  28. Pérez-Vera P, Montero O, Salas C. Bases genéticas de la leucemia. In: Pimentel E, Ortiz R, Breña M. Tópicos de genética. Dirección de difusión y promoción de la investigación y los estudios avanzados. México; 2006, p. 297-318.

  29. Pérez-Vera P, Montero O. Citogenética en leucemias. In: Rivera Luna R. Hemato-oncología pediátrica. México: Editores de textos mexicanos; 2006, p. 179-91.

  30. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008; 14(5): 355-68.

  31. Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia-a review of 101 cases. Ann Oncol 2008; 19(9): 1634-8.

  32. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102(1): 43-51.

  33. Schoch C, Kern W, Schinittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapyrelated acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18(1): 120-5.

  34. Slovak ML, Bedell V, Popplewell L, Arber DA, Schoch C, Slater R. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer 2002; 33(4): 379-94.

  35. Bloomfield CD, Archer KJ, Mrózek K, Lillington DM, Kaneko Y, Head DR, Dalcin P, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33(4): 362-78.

  36. Andersen MT, Andersen MK, Christiansen DH, Pedersen-Bjergaard J. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features. Leukemia 2008; 22: 951-5.

  37. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, VanrumbekeM, et al. Methylation of the p15INK4B gene in myelodisplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91(8): 2985-90.

  38. Voso MT, D’Aló F, Greco M, Fabiani E, Criscuolo M, Migliara G, Pagano L, et al. Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact 2010; 184: 46-9.

  39. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7 and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003; 17: 1813-9.

  40. Au WY, Fung A, Man C, Ma SK, Wan TS, Liang R, Kwong YL. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br J Haematol 2003; 120(6): 1062-5.

  41. Solomon PR, Munirajan AK, Nobuo Tsuchida, Kottampatti Muthukumarasamy, Andiappan Rathinavel, Selvam GS, Shanmugam G. Promoter hypermethylation analysis in myelodysplastic syndromes: Diagnostic & prognostic implication. Indian J Med Res 2008; 127: 52-7.

  42. Carow CE, Kim E, Hawkins AL, Webb HD, Griffin CA, Jabs EW, Civin CI, et al. Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12- q13. Cytogenet Cell Genet 1995; 70(3-4): 255-7.




2020     |     www.medigraphic.com